For hospital systems, health plans, and accountable care organizations facing readmission penalties and value-based care pressure, home infusion therapy represents one of the most evidence-backed strategies for reducing unnecessary inpatient days and 30-day readmissions. The data supporting this is not anecdotal, it comes from over three decades of OPAT (outpatient parenteral antibiotic therapy) research, real-world payer claims analysis, and comparative effectiveness studies.
This article reviews the clinical evidence, identifies the patient populations that benefit most, and explains how a specialty pharmacy like
Pharmko supports discharge teams in executing this strategy safely.
The Readmission Problem Home Infusion Addresses
Hospital readmissions within 30 days represent one of the most costly and preventable quality failures in the US healthcare system. CMS estimates that approximately 15–20% of Medicare patients are readmitted within 30 days of discharge, generating tens of billions of dollars in costs annually and triggering Hospital Readmissions Reduction Program (HRRP) penalties for institutions with above-average rates.
For specific diagnoses, sepsis, pneumonia, heart failure, and surgical site infections, the readmission risk is particularly high when patients are discharged before completing their treatment course.
Home infusion therapy allows discharge to proceed while treatment continues safely at home, extending the effective treatment window without extending the inpatient stay.
What the Evidence Shows
OPAT and infection-related readmissions
The most robust outcomes data for home infusion comes from OPAT, outpatient IV antibiotic therapy for serious infections including osteomyelitis, endocarditis, skin and soft tissue infections, and pneumonia. Key findings from the published literature:
- OPAT completion rates consistently exceed 85% across multiple large cohort studies, with clinical cure rates comparable to inpatient antibiotic therapy for most infection types
- Readmission rates for patients completing OPAT through a structured specialty pharmacy program range from 8–12%, compared to 15–20% for similar diagnosis groups discharged to lower levels of support
- A 2019 meta-analysis in Open Forum Infectious Diseases found that OPAT was associated with significantly lower complication rates than extended inpatient stays for comparable infections, driven in part by the reduced exposure to hospital-acquired pathogens
- Infectious disease society guidelines (IDSA, BSAC) now recommend OPAT as the standard of care for stable patients with infections requiring 2–6 weeks of IV antibiotics
TPN and nutrition-related readmissions
For patients with intestinal failure, short bowel syndrome, and other conditions requiring parenteral nutrition, home TPN prevents the recurrent hospitalizations that occur when patients cannot maintain adequate nutrition as outpatients. Research consistently shows that stable home TPN patients have significantly lower hospital utilization compared to matched patients who do not receive structured home nutrition support.
Biologics and chronic disease management
For patients receiving IV biologics for autoimmune diseases, Remicade for Crohn's, Ocrevus for MS, Benlysta for lupus, maintaining consistent infusion schedules prevents the disease flares that drive ER visits and admissions. Pharmacy-coordinated home infusion programs have been shown to improve adherence to biologic maintenance schedules compared to infusion center models, particularly for patients with transportation barriers or complex daily schedules.
Why Home Infusion Is Safer Than Often Assumed
Physician hesitation about home infusion often centers on safety, the concern that without direct clinical oversight, complications will be missed or managed suboptimally. The evidence does not support this concern when therapy is delivered through an accredited specialty pharmacy with structured clinical oversight.
A well-designed home infusion program includes pharmacist review of every order, nurse home visits, 24/7 clinical on-call access, regular lab monitoring, and direct physician communication. This model mirrors, and in some dimensions exceeds, the monitoring that occurs during an uncomplicated inpatient stay. Our guide on
home infusion vs. hospital infusion reviews the clinical safeguards in detail.
The key variable is the pharmacy. An accredited, clinically sophisticated specialty pharmacy creates the oversight structure that makes home infusion safe. A pharmacy that functions primarily as a delivery service does not.
Cost Implications for Health Systems and Payers
The cost advantage of home infusion over inpatient care is substantial and well-documented. CMS data and payer analyses consistently show:
- Home infusion costs 60–80% less per day than equivalent inpatient care for antibiotic therapy
- Home TPN costs approximately 50–70% less than inpatient TPN administration
- Reduced readmission rates translate directly to avoided HRRP penalties for health systems
- For value-based contracts and ACOs, home infusion reduces total cost of care while maintaining quality metrics
For discharge planning teams building the case for expanded home infusion utilization within their institutions, Pharmko's clinical and financial outcomes data is available for review.
How Pharmko Supports Discharge Planning Teams
Pharmko works directly with hospital case managers, discharge planners, and attending physicians to facilitate timely, safe transitions to home infusion. Our referral team accepts urgent discharge requests and can typically initiate therapy within 24–72 hours of referral. Our guide on
how to refer a patient to home infusion covers the documentation and process in detail.
For infection-related discharges, our
home IV antibiotic therapy guide provides a patient-facing overview of what OPAT involves that can be shared directly with patients and families at discharge.
Pharmko's
provider resources page includes referral forms, documentation checklists, and contact information for our clinical coordination team.
→
Contact Pharmko to discuss a discharge partnership:
1-877-540-2003
